Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan V Boddy

Showing results (1-10 of 82) with videos related to

Pageof 9
Sort By:
British Journal of Clinical Pharmacology|July 18, 2006
Recent developments in the clinical pharmacology of classical cytotoxic chemotherapyAlan V Boddy
Expert Opinion on Drug Metabolism & Toxicology|September 17, 2011
Pharmacogenetics of genes across the doxorubicin pathwayDavid Jamieson, Alan V Boddy
Seminars in Fetal & Neonatal Medicine|April 3, 2012
Chemotherapy in newborns and preterm babiesGareth J Veal, Alan V Boddy
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 2, 2012
Carboplatin dosing in infants with retinoblastoma: a case for therapeutic drug monitoringGareth J Veal, Alan V Boddy
British Journal of Clinical Pharmacology|October 29, 2020
Is there scope for better individualisation of anthracycline cancer chemotherapy?Benedetta C Sallustio, Alan V Boddy
Expert Opinion on Drug Metabolism & Toxicology|April 18, 2014
Sources of preanalytical error in pharmacokinetic analyses - focus on intravenous drug administration and collection of blood samplesMiriam Krischke, Alan V Boddy, Joachim Boos
British Journal of Clinical Pharmacology|April 7, 2020
Potential for pharmacokinetic interactions between Schisandra sphenanthera and bosutinib, but not imatinib: in vitro metabolism study combined with a physiologically-based pharmacokinetic modelling approachJeffry Adiwidjaja, Alan V Boddy, Andrew J McLachlan
Expert Opinion on Drug Metabolism & Toxicology|June 3, 2016
The implications of genetic variation for the pharmacokinetics and pharmacodynamics of aromatase inhibitorsXiaoman Liu, Siew-Kee Low, Alan V Boddy
European Journal of Clinical Pharmacology|January 20, 2022
Physiologically based pharmacokinetic model predictions of natural product-drug interactions between goldenseal, berberine, imatinib and bosutinibJeffry Adiwidjaja, Alan V Boddy, Andrew J McLachlan
Pharmaceutical Research|June 13, 2020
Physiologically-Based Pharmacokinetic Predictions of the Effect of Curcumin on Metabolism of Imatinib and Bosutinib: In Vitro and In Vivo DisconnectJeffry Adiwidjaja, Alan V Boddy, Andrew J McLachlan
Pageof 9

Showing results (1-10 of 82) with videos related to

Sort By:
Pageof 9
British Journal of Clinical Pharmacology|July 18, 2006
Recent developments in the clinical pharmacology of classical cytotoxic chemotherapyAlan V Boddy
Expert Opinion on Drug Metabolism & Toxicology|September 17, 2011
Pharmacogenetics of genes across the doxorubicin pathwayDavid Jamieson, Alan V Boddy
Seminars in Fetal & Neonatal Medicine|April 3, 2012
Chemotherapy in newborns and preterm babiesGareth J Veal, Alan V Boddy
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 2, 2012
Carboplatin dosing in infants with retinoblastoma: a case for therapeutic drug monitoringGareth J Veal, Alan V Boddy
British Journal of Clinical Pharmacology|October 29, 2020
Is there scope for better individualisation of anthracycline cancer chemotherapy?Benedetta C Sallustio, Alan V Boddy
Expert Opinion on Drug Metabolism & Toxicology|April 18, 2014
Sources of preanalytical error in pharmacokinetic analyses - focus on intravenous drug administration and collection of blood samplesMiriam Krischke, Alan V Boddy, Joachim Boos
British Journal of Clinical Pharmacology|April 7, 2020
Potential for pharmacokinetic interactions between Schisandra sphenanthera and bosutinib, but not imatinib: in vitro metabolism study combined with a physiologically-based pharmacokinetic modelling approachJeffry Adiwidjaja, Alan V Boddy, Andrew J McLachlan
Expert Opinion on Drug Metabolism & Toxicology|June 3, 2016
The implications of genetic variation for the pharmacokinetics and pharmacodynamics of aromatase inhibitorsXiaoman Liu, Siew-Kee Low, Alan V Boddy
European Journal of Clinical Pharmacology|January 20, 2022
Physiologically based pharmacokinetic model predictions of natural product-drug interactions between goldenseal, berberine, imatinib and bosutinibJeffry Adiwidjaja, Alan V Boddy, Andrew J McLachlan
Pharmaceutical Research|June 13, 2020
Physiologically-Based Pharmacokinetic Predictions of the Effect of Curcumin on Metabolism of Imatinib and Bosutinib: In Vitro and In Vivo DisconnectJeffry Adiwidjaja, Alan V Boddy, Andrew J McLachlan
Pageof 9